List of Excipients in Branded Drug LABETALOL HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	0641-6252	ANHYDROUS DEXTROSE
Hikma Pharmaceuticals USA Inc	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	0641-6252	CITRIC ACID MONOHYDRATE
Hikma Pharmaceuticals USA Inc	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	0641-6252	EDETATE DISODIUM
Hikma Pharmaceuticals USA Inc	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	0641-6252	SODIUM HYDROXIDE

Generic Drugs Containing LABETALOL HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc.	labetalol hydrochloride	0143-9320	ANHYDROUS DEXTROSE
Hikma Pharmaceuticals USA Inc.	labetalol hydrochloride	0143-9320	EDETATE DISODIUM
Hikma Pharmaceuticals USA Inc.	labetalol hydrochloride	0143-9320	METHYLPARABEN
Hikma Pharmaceuticals USA Inc.	labetalol hydrochloride	0143-9320	PROPYLPARABEN

What are the Most Frequently-Used Excipients in LABETALOL HYDROCHLORIDE?

# Of NDCs	Excipient
8	ALUMINUM OXIDE
2	ANHYDROUS CITRIC ACID
20	ANHYDROUS DEXTROSE
40	ANHYDROUS LACTOSE

Excipients Strategy and Commercial Opportunities for Labetalol Hydrochloride

Last updated: March 1, 2026

What are the key considerations in developing an excipient strategy for labetalol hydrochloride?

Labetalol hydrochloride is a non-selective beta-blocker used primarily for hypertension management. Its formulation requires careful selection of excipients to ensure stability, bioavailability, patient compliance, and manufacturing efficiency. Key considerations include:

• Stability: Excipients must maintain drug stability under various storage conditions, particularly because labetalol is sensitive to moisture and temperature.
• Solubility and Dissolution: Since labetalol hydrochloride is water-soluble, excipients should facilitate rapid dissolution without causing complexation or precipitation.
• Compatibility: Compatibility with active pharmaceutical ingredient (API) to prevent degradation or inactivation.
• Bioavailability Enhancement: Excipients that improve absorption, such as surfactants or permeability enhancers.
• Formulation Type: Whether oral tablets, injectables, or controlled-release forms dictates excipient choice.

Common excipients include diluents (lactose, microcrystalline cellulose), binders (polyvinylpyrrolidone), disintegrants (croscarmellose sodium), lubricants (magnesium stearate), and stabilizers (titanium dioxide).

How does excipient choice influence commercial opportunities?

Excipients can influence product differentiation, regulatory approval, manufacturing costs, and patient adherence, affecting commercial success:

• Differentiation Through Delivery Platforms: Using innovative excipients like lipid-based carriers or polymers can produce controlled-release formulations, expanding market opportunities.
• Cost Optimization: Selecting cost-effective excipients can improve profit margins, particularly for generic versions.
• Regulatory Advantages: Utilizing excipients with established safety profiles streamlines approval processes; unique excipients may face additional scrutiny.
• Patents and Proprietary Formulations: Developing proprietary excipient combinations or delivery systems can create barriers to competition and extend patent life.
• Patient Compliance: Taste-masking excipients and easy-to-swallow formats can increase market share, especially in pediatric or geriatric segments.

What are emerging trends in excipient strategies for labetalol hydrochloride?

• Lipid-Based Formulations: Liposomes and solid lipid nanoparticles improve bioavailability and stability. These approaches are gaining traction for labetalol to enhance absorption and extend release.
• Polymer-Modified Delivery: Biodegradable polymers like PLGA enable sustained release, reducing dosing frequency.
• Natural and Plant-Derived Excipients: Growing demand for natural excipients increases opportunities for products with lower regulatory hurdles and consumer appeal.
• Functional Excipients: Excipients with multiple roles, such as multifunctional disintegrants or stabilizers, streamline formulation and manufacturing.

What commercial opportunities exist in excipient supply and innovation?

• Excipients Market Size: The global excipients market is projected to reach USD 10.5 billion by 2027 with a CAGR of 5.3% (Research and Markets, 2022).
• Generic Formulations: Cost-efficient excipient sourcing supports high-volume production of generics.
• Innovative Platforms: Licensing or developing novel excipients and delivery systems can command premium pricing and create IP assets.
• Regulatory Support: Companies that offer excipients with GRAS status and extensive safety data can expedite regulatory pathways.
• Collaborations and Partnerships: Partnering with excipient manufacturers enables tailored solutions and accelerates product timelines.

Summary of regulatory landscape

• FDA Guidance: Excipients designated as inactive ingredients must have designate GRAS status or equivalent.
• EMA: Excipients must meet the European Pharmacopeia standards.
• Global Variations: Formulations tailored to regional regulations in Asia and Latin America require compliant excipients, expanding market customization.

Key Takeaways

• Excipient selection impacts stability, bioavailability, manufacturing, and market differentiation for labetalol hydrochloride formulations.
• Innovations such as lipid-based and polymer delivery systems offer pathways for premium products and extended patent protection.
• Cost-effective and regulatory-compliant excipients support large-scale generic manufacturing.
• Emerging trends favor natural, multifunctional excipients and delivery platforms that improve patient adherence.
• Market opportunities include high-volume generic production, proprietary delivery systems, and strategic partnerships.

FAQs

Q1: How does excipient selection affect labetalol hydrochloride stability?
A: Excipients such as stabilizers and moisture barriers prevent degradation caused by hydrolysis, oxidation, or moisture exposure.

Q2: Are there patent opportunities related to excipient strategies for labetalol?
A: Yes, proprietary excipient combinations or novel delivery systems can secure patent protection and prevent generic competition.

Q3: What excipients are preferred for controlled-release formulations of labetalol?
A: Biodegradable polymers like PLGA or lipid-based carriers enable sustained release and improve therapeutic profiles.

Q4: How can natural excipients be integrated into labetalol formulations?
A: Natural polymers like starch or cellulose derivatives can replace synthetic excipients, appealing to markets with natural product demands.

Q5: What regulatory hurdles exist for novel excipients in labetalol formulations?
A: Novelly used excipients require extensive safety and compatibility data, potentially delaying approval compared to established excipients.

References

1. Research and Markets. (2022). Excipients market by Type, Application, and Region — Global Forecast to 2027.
2. US FDA. (2018). Guidance for Industry: Nonclinical Testing of Inte...